Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

Infantile Nystagmus Syndrome Clinical Trial

Official title:

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01312402
• Other study ID #: 101109
• Status: Completed
• Phase: Phase 4
• First received: January 21, 2011
• Last updated: June 24, 2014
• Start date: January 2011
• Est. completion date: March 2014

Study information

• Verified date: June 2014
• Source: Akron Children's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective, single crossover, double-masked, controlled clinical trial that will use topical brinzolamide (Azopt)ophthalmic medication to try to improve the nystagmus and visual consequences of nystagmus in patients with infantile nystagmus syndrome (INS). Subjects will undergo a clinical exam, questionnaire and eye movement recordings on day 1 and then receive either topical Azopt or placebo three times a day in both eyes for days 2,3 and 4 followed on the morning of day 5 by a repeat clinical exam, questionnaire and eye movement recordings. After at least one week, this protocol is repeated with the crossover regimen being taken by the subject. One week after all medications are discontinued, another clinical exam is done before study discharge. The hypothesis is that nystagmus and associated visual symptoms will be improved while on the Azopt compared to the placebo. There will be a total of 5 visits over a 1-2 month period.

Description:

5 subjects are expected to be enrolled in the study. Each subject will be in the study for approximately 1 month.

Efficacy will be assessed by:

• ETDRS Visual Acuity Testing of Binocular Best Corrected Visual Acuity In The Nystagmus Null Zone

• The Validated Amblyopia & Strabismus Ocular Motor Questionnaire

• Eye Movement Recording Data Analysis of The Nystagmus Waveform

Safety will be evaluated by:

• Ocular signs and symptoms

• Visual acuity (uncorrected and best corrected)

• Slit lamp exam and Intraocular Pressure

• Systemic signs and symptoms

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Age; greater than 12 years old and able to cooperate for full study protocol

• Subject able to understand and sign informed consent

• Subject able to participate in complete ophthalmic and ocular motility evaluation

• Subjects with Infantile Nystagmus Syndrome diagnosed by clinical evaluation and eye movement recordings

• Best-binocular visual acuity in null position 20/50 to 20/200 inclusive using ATS or ETDRS vision testing

• Subject/family able and willing to make the required study visits

• No previous ophthalmic treatment for nystagmus other than for refractive error

Exclusion Criteria:

• Any current use of systemic or topical medications (traditional or non-traditional)

• History of ocular surgery, trauma or chronic ocular disease other than amblyopia

• Systemic diseases requiring medication or other treatments that are known to affect the ocular motor system (e.g., depression, seizure disorders, psychosis)

• Behavioral or neurological disorders which interfere with the study

• Physical or mental impairment precluding study compliance

• Participation in any study involving an IND investigational drug within the past year

• Individual (female) is pregnant, nursing or planning a pregnancy (The safety of Azopt for use during pregnancy has NOT been determined.)

• Periodicity or aperiodicity of INS present on eye movement recordings

• Allergy to sulfa or other components of Azopt solution

Related Conditions & MeSH terms

• Infantile Nystagmus Syndrome
• Syndrome

Intervention

Drug:
• topical brinzolamide 1% in 5mL ophthalmic medication
1 drop three times a day in both eyes on days 2,3 and 4
• Placebo in 5 mL dispenser
Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4

Locations

Country	Name	City	State
United States	Akron Children's Hospital	Akron	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Akron Children's Hospital

Country where clinical trial is conducted

United States, 

References & Publications (6)

Dell'Osso LF, Jacobs JB. An expanded nystagmus acuity function: intra- and intersubject prediction of best-corrected visual acuity. Doc Ophthalmol. 2002 May;104(3):249-76. — View Citation

Hertle RW, Anninger W, Yang D, Shatnawi R, Hill VM. Effects of extraocular muscle surgery on 15 patients with oculo-cutaneous albinism (OCA) and infantile nystagmus syndrome (INS). Am J Ophthalmol. 2004 Dec;138(6):978-87. — View Citation

Hertle RW, Dell'Osso LF, FitzGibbon EJ, Thompson D, Yang D, Mellow SD. Horizontal rectus tenotomy in patients with congenital nystagmus: results in 10 adults. Ophthalmology. 2003 Nov;110(11):2097-105. — View Citation

Hertle RW, Dell'Osso LF, FitzGibbon EJ, Yang D, Mellow SD. Horizontal rectus muscle tenotomy in children with infantile nystagmus syndrome: a pilot study. J AAPOS. 2004 Dec;8(6):539-48. — View Citation

Jacobs JB, Dell'Osso LF, Hertle RW, Acland GM, Bennett J. Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2865-75. — View Citation

Jacobs JB, Dell'Osso LF, Wang ZI, Acland GM, Bennett J. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA. Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4685-92. doi: 10.1167/iovs.09-3387. Epub 2009 May 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best Corrected Binocular Visual Acuity	Early Treatment of Diabetic Retinopathy Study Vision Testing Protocol of Best corrected Binocular Acuity	1 week
Secondary	Visual Function	THe Validated Amblyopia and Visual Function Questionnaire will be administered	5 Days